|Bid||64.68 x 800|
|Ask||64.68 x 900|
|Day's Range||64.57 - 65.38|
|52 Week Range||53.63 - 71.70|
|Beta (5Y Monthly)||0.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.44 (2.17%)|
|Ex-Dividend Date||Feb 24, 2022|
|1y Target Est||71.80|
AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.
AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc in a deal worth up to $1.27 billion on Tuesday, in a move to bolster its roster of therapies to treat blood cancers. At the heart of the deal is the U.S.-based company's early stage experimental treatment for a form of Non-Hodgkin's lymphoma, a type of cancer that involves the growth of abnormal white blood cells that can lead to the emergence of tumours. The Anglo-Swedish drugmaker - whose key blood cancer drug Calquence generated sales of more than $1.2 billion last year - plans to acquire all outstanding equity of TeneoTwo for an upfront payment of $100 million, with additional milestone-related payments of up to $1.17 billion.